New acne treatment: GSK’s topical Fabior Foam gets FDA approval
A new acne treatment from GlaxoSmithKline (NYSE:GSK) now has marketing approval in the United States to tackle pimples and blackheads in acne sufferers.
Tazarotene, which will be marketed under the name Fabior Foam, is a topical foam developed to treat acne vulgaris. Fabior now has U.S. Food and Drug Administration approval to treat the moderate-to-severe acne in patients who are 12 or older.
Fabior was developed by GSK subsidiary Stiefel Laboratories, the dermatology products company that GSK acquired in 2009 for $2.9 billion as the company made a play to diversify its drug portfolio beyond the slate of blockbuster drugs …
Read User's Comments0